AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01908309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol 320
Study NCT01031628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: 400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Study NCT01031628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Study NCT01031628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: 400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Study NCT00801463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium wilfordii (TW)
Description: Pre 30mg/d +TW 120 mg/d, po for 12 weeks
Study NCT04229810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STD-02
Description: Conventional standardized ventilatory approach.
Study NCT04229810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iOLA-iHFNC
Description: Indivudualized perioperative open lung ventilatory approach.
Study NCT02281123 — intervention group
Intervention type: OTHER
Intervention: SF36 (QQoL)
Description: use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
Study NCT00940745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Aspiration and Thrombolysis
Description: Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
Study NCT03552601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional speed
Description: ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
Study NCT03552601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: faster speed
Description: ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
Study NCT00940745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Study NCT04155970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.
Study NCT04155970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-informed home management booklet
Description: The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
Study NCT02145845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable SIS
Description: Injectable SIS
Study NCT02522728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CR
Description: Implantation of Knee Prosthesis
Study NCT02522728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PS
Description: Implantation of Knee Prosthesis
Study NCT01099917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maitake
Description: Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test.
Study NCT00980655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose.
Study NCT00980655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23vPS
Description: 0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
Study NCT02432833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENVARSUS®
Description: Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
Study NCT02432833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROGRAF®
Description: Prograf® hard capsules, twice daily, oral formulation
Study NCT02432833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAGRAF®
Description: Advagraf® prolonged-release hard capsules, once daily, oral formulation
Study NCT01814215 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Keys to Healthy Family Child Care Homes
Description: The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
Study NCT03435731 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dual Therapy
Description: Concomitant use of Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splint (MAS) therapeutic devices.
Study NCT01649154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus
Study NCT00795223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine and bupivacaine
Description: 0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
Study NCT00795223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal morphine and marcaine
Description: 0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
Study NCT00795223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine and bupivacaine
Description: 0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
Study NCT00795223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine and bupivacaine
Description: 0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
Study NCT02313389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Methotrexate, Temozolomide
Description: Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
Study NCT02526498 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
Study NCT02526498 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo APBI using HDR brachytherapy
Study NCT02526498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03376750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO - OP
Description: CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
Study NCT02180750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Work Therapy
Study NCT02180750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Pediatric clinic, ART
Study NCT01814215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keys to Healthy Family Child Care Homes
Description: The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
Study NCT02185456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository
Description: The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
Study NCT02185456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: oral metronidazole 500 mg twice a day for 7 days
Study NCT02185456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: oral metronidazole 500 mg twice a day for 7 days
Study NCT00255164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
Study NCT01647542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets
Study NCT01647542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-875 Placebo
Description: TAK-875 placebo-matching tablets
Study NCT04684433 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT02117986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colistin
Description: One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
Study NCT02117986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin
Description: One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
Study NCT01255956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin eluting stent implantation
Description: Rapamycin eluting stent implantation for in-stent restenosis treatment
Study NCT01255956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting balloon catheter
Description: Paclitaxel eluting balloon catheter for in-stent restenosis treatment
Study NCT03993210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Fingerprinting (MRF)
Description: In MRF, multiple tissue properties are acquired simultaneously.
Study NCT03993210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Fingerprinting (MRF)
Description: In MRF, multiple tissue properties are acquired simultaneously.
Study NCT00255164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
Study NCT00255164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study NCT02404129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Turn 180 test
Description: The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor.
Study NCT03430856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Tregopil
Description: Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
Study NCT03430856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
Study NCT03581916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-JNJ-64326067
Description: 18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
Study NCT03993210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-space Trajectory Imaging (QTI)
Description: By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
Study NCT03993210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-space Trajectory Imaging (QTI)
Description: By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
Study NCT03993210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging Machine (MRI)
Description: MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
Study NCT03993210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging Machine (MRI)
Description: MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
Study NCT01167452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole/trimethoprim
Description: 2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
Study NCT03369873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance Manual
Description: The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
Study NCT03831919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNC III
Description: Hoya SYNC III design spectacle lenses
Study NCT03831919 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: single vision lenses
Description: single vision spectacle lenses with no addition
Study NCT02521597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellscope
Description: The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
Study NCT02521597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional otoscope
Description: Use of a regular otoscope
Study NCT02482753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg, administered orally twice per week (BIW)
Study NCT02482753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg, PO daily
Study NCT02482753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: 25 mg, PO daily
Study NCT02482753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered orally twice per week (BIW)
Study NCT01218971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 190 mg
Description: naltrexone for extended-release injectable suspension
Study NCT01218971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: naltrexone for extended-release injectable suspension
Study NCT01613079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F
Description: Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
Study NCT01613079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
Study NCT01613079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
Study NCT04003623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib administered orally once daily.
Study NCT03944278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Laser
Description: Thulium laser for skin resurfacing procedures
Study NCT01673087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone
Description: 750 mcg, oral, administered twice, 3.5 hours apart
Study NCT01673087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration.
Study NCT01673087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortrosyn
Description: 250 mcg, IV, bolus, in the afternoon.
Study NCT01673087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin ovine triflutate
Description: 100 mcg, IV, over 30 seconds, in the afternoon.
Study NCT01371825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (SBC-102)
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
Study NCT02963675 — intervention group
Intervention type: OTHER
Description: external unexposed reference group
Study NCT03680352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime/AAI101
Description: Fixed dose combination of cefepime and AAI101
Study NCT01120873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamin 3D
Description: Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
Study NCT03802734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindful meditation phone app
Description: Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
Study NCT01583504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection of steroid and local anaesthetic
Description: 2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
Study NCT01583504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided injection of steroid and local anaesthetic
Description: 2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.